Doxazosin for Psychostimulant Dependence
This study is currently recruiting participants.
Verified December 2012 by University of Arkansas
Sponsor:
University of Arkansas
Collaborators:
Baylor College of Medicine
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT01371851
First received: June 9, 2011
Last updated: December 6, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Psychostimulant dependence is a major public health problem and no medications have been shown to be very effective in treating this disorder. Thus, the investigators wish to study whether a blood pressure drug thought to reduce drug craving through its interaction at particular adrenergic receptors - doxazosin - can delay relapse relative to placebo in psychostimulant dependent participants who attain 2 weeks of abstinence. Our hypothesis is that doxazosin will prolong abstinence relative to placebo in psychostimulant dependent participants.
| Condition | Intervention | Phase |
|---|---|---|
|
Methamphetamine or Cocaine Dependence |
Drug: Doxazosin extended release |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Clinical Efficacy of Doxazosin for Psychostimulant Dependence |
Resource links provided by NLM:
Further study details as provided by University of Arkansas:
Primary Outcome Measures:
- First Methamphetamine- or Cocaine-Positive Urine [ Time Frame: thrice-weekly urine samples (two weeks) ] [ Designated as safety issue: No ]Time to lapse/relapse will be determined via thrice-weekly urine drug screens.
| Estimated Enrollment: | 60 |
| Study Start Date: | June 2011 |
| Estimated Study Completion Date: | June 2014 |
| Estimated Primary Completion Date: | April 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Doxazosin
Doxazosin extended release will be administered initially at 4 mg/day. On day 8 the dose is increased to 8 mg/day and the participant is maintained on the study until the end of the trial.
|
Drug: Doxazosin extended release
initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
|
|
Placebo Comparator: Placebo
Participants will be maintained on placebo (cellulose) throughout the trial.
|
Drug: Doxazosin extended release
initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
|
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- 18-55 years old
- Methamphetamine OR cocaine dependence, as assessed by the substance abuse section of the Structured Clinical Interview for DSM-IV.
- At least weekly self-reported methamphetamine OR cocaine use during a preceding three month period
- Urine toxicology screen positive for methamphetamine or methamphetamine metabolite OR cocaine or cocaine metabolite
- Women of childbearing age must have a negative pregnancy test, agree to adequate contraception to prevent pregnancy during the study, agree to monthly pregnancy testing and not be nursing
Exclusion Criteria:
- Suicide attempts within the past 12 months or suicidal ideations or psychotic symptoms in the past 6 months as determined by a study physician.
- Current opioid, alcohol or sedative physical dependence or dependence on both cocaine and methamphetamine
- Major cardiovascular disorder that contraindicates study participation (e.g., history of myocardial infarction, stroke, congestive heart failure, cardiac arrhythmia, significant hypertension [i.e., >170 SBP or >110 DBP] or an unstable medical condition (e.g., untreated bacterial infection) as determined by the study physician.
- Any history or evidence suggestive of seizure disorder or brain injury
- Subjects needing or planning cataract surgery.
- History of schizophrenia, major depression, or bipolar type I disorder
- Organic brain disease or dementia assessed by physician
- Use of medications that would be expected to have major interaction with doxazosin (e.g. atanazavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, or voriconazole or any other potent 3A4 inhibitor.,)
- Any previous medically adverse reaction to methamphetamine or cocaine, including loss of consciousness, chest pain, or epileptic seizure
- Medical contraindication to receiving doxazosin (e.g. liver problems or allergies to other to other quinazolines such as prazosin or terazosin)
- Severe gastrointestinal disorder as determined by physician
- Liver function tests (i.e., liver enzymes) greater than three times normal levels
- Systolic blood pressure > 170 mmHg or < 90 mmHg, diastolic blood pressure > 110 mmHg or < 60 mmHg, or heart rate of > 110 beats/min or < 55 beats/min.
- Supine blood pressure of 100/65 mm Hg or lower, a seated blood pressure of 90/60 mm Hg or lower, or an orthostatic change of >20mm Hg systolic or 10 mm Hg diastolic on standing.
- Have evidence of untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease
- Have symptomatic HIV or are taking antiretroviral medication
- Have asthma or currently use theophylline or other sympathomimetics
- Participants with estimated glomerular filtration rate < 30 ml/min.
- Pregnant or nursing female
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01371851
Contacts
| Contact: Srinivasa Gokarakonda | 501-526-7969 | SBGokarakonda@uams.edu |
Locations
| United States, Arkansas | |
| UAMS Psychiatric Research Institute | Recruiting |
| Little Rock, Arkansas, United States, 72205 | |
| Contact: Srinivasa Govindanin 501-526-7969 | |
| Principal Investigator: Alison Oliveto, PhD | |
| Sub-Investigator: Michael Mancino, MD | |
Sponsors and Collaborators
University of Arkansas
Baylor College of Medicine
More Information
No publications provided
| Responsible Party: | University of Arkansas |
| ClinicalTrials.gov Identifier: | NCT01371851 History of Changes |
| Other Study ID Numbers: | 2-P50-DA018197-DoxMeth |
| Study First Received: | June 9, 2011 |
| Last Updated: | December 6, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Cocaine-Related Disorders Substance-Related Disorders Mental Disorders Doxazosin Central Nervous System Stimulants Antihypertensive Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions |
Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 19, 2013